Enara Bio
France
activeseries-b
series-b
Stage
1
Investors
About
Enara Bio is a biopharmaceutical company pioneering the discovery of novel Dark Antigens and the development of bispecific T-cell engagers for solid tumors. It utilizes its proprietary EDAPT platform to discover cancer-specific targets derived from previously unexplored regions of the genome, known as the 'dark genome', and employs the EnTiCE platform to develop potent immunotherapies.
Explore Enara Bio's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.